facebook button LEAP-008: Second Line Lenvatinib and Pembrolizumab
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

LEAP-008: Second Line Lenvatinib and Pembrolizumab

Sponsor: Merck Sharp & Dohme Corp.

A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non- small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy.